Cross-source consensus on what matters today in genetics and genomics — drawn from 16 trusted public sources including NHGRI, the CDC, NHS England, Genomics England, the PHG Foundation, the Wellcome Sanger Institute, and peer-reviewed open-access journals.
Last updated: · browse archive
The FDA has approved Scholar Rock's Isembyld for spinal muscular atrophy, the first therapy to address the muscle-wasting component of the disease when combined with an SMN2-targeting agent.
A bioRxiv preprint presents evidence that some individuals express brain APOE transcripts that differ from their genomically encoded allele, raising questions about how APOE risk variants are expressed.
A study finds that cisplatin and carboplatin leave mutational signatures in children's livers that accelerate cellular ageing and may raise long-term cancer risk.
A bioRxiv preprint presents population-genetic evidence that a common STING allele impairing innate antiviral immunity was selected outside Africa and may have contributed to catastrophic post-Columbian smallpox mortality.
Researchers have found that the three-dimensional folding of DNA is altered in several brain cell populations affected by Alzheimer's disease, changing how key genes are switched on and off.
A preprint from a congenic mouse study identifies an intragenic suppressor variant that converts a lethal SCN8A gain-of-function phenotype into graded outcomes, illuminating the narrow window for NaV1.6-targeted therapies.
Researchers examining APOE isoform effects across diverse human populations report that the ε4 allele's associations with cholesterol biology and disease risk differ markedly depending on environmental context.
A genetically humanised mouse study finds that the human accelerated region HACNS1 speeds up craniofacial development while slowing limb development, implicating regulatory enhancers in the evolution of human-specific developmental timing.
The HARBOR trial of del-desiran for myotonic dystrophy type 1 did not meet its primary endpoint, dealing a second major setback to Novartis within days.
Zanvastro, an antisense oligonucleotide from Ionis Pharmaceuticals, has received FDA approval for Alexander disease — a rare, fatal neurological disorder with no previously approved therapy.
About Genetic Current
Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.
Join the Evagene Alpha Waiting List